Furthermore, our data showed a significant hazard ratio (HR) of CD133 in both sets and LC3 and CD46 in the validation set in OS of liver disease patients (Figure S6), unlike the public DB containing only liver cancer patients (Figure 2B). This evidence concerns the gene MAP1LC3A and liver cancer.